Manal F. Abdelmalek, MD, MPH is Director of Hepatology and institutional lead for investigator-initiated and industry-sponsored multicenter clinical studies at Mayo Clinic, USA. Until recently, she was tenured Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University.
Since first reporting NASH as a case of cryptogenic cirrhosis over 20 years ago, her research area of interest has focused on risk factors for NAFLD acquisition, fibrosis progression, and discovery of new and novel therapeutic interventions. She has expertise in the design and conduct of investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD. Her expertise includes transitioning new compounds to first-in-man early phase studies and the translation of clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression.